Home › Endocyte's ovarian cancer drug fails trial, shares sink
 

Keywords :   


Endocyte's ovarian cancer drug fails trial, shares sink

2014-05-04 10:59:52| Biotech - Topix.net

Merck & Co Inc and Endocyte Inc said they had stopped a late-stage trial of their experimental ovarian cancer drug as it failed to improve survival rates without the cancer worsening, sending Endocyte's shares tumbling as much as 63 percent.

Tags: trial drug cancer shares

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.06Tropical Storm Beryl Public Advisory Number 3A
29.06Summary for Tropical Storm Beryl (AT2/AL022024)
29.06Tropical Storm Beryl Graphics
29.06Eastern North Pacific Tropical Weather Outlook
29.06Atlantic Tropical Weather Outlook
29.06Weekly Recap: PPG, Hempel, Beckers Group Top This Weeks Stories
29.06Tropical Storm Beryl Graphics
29.06Tropical Storm Beryl Forecast Discussion Number 3
More »